Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization

Prostate cancer is the most frequently diagnosed male visceral cancer and the second leading cause of cancer death in the United States. Standard tests such as prostate-specific antigen (PSA) measurement have poor specificity (33%) resulting in a high number of false positive reports. Consequently t...

Full description

Saved in:
Bibliographic Details
Published inJournal of Cancer Vol. 7; no. 8; pp. 1002 - 1009
Main Authors Truong, Quach, Justiniano, Irene O, Nocon, Aline L, Soon, Julie T, Wissmueller, Sandra, Campbell, Douglas H, Walsh, Bradley J
Format Journal Article
LanguageEnglish
Published Australia Ivyspring International Publisher 01.01.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Prostate cancer is the most frequently diagnosed male visceral cancer and the second leading cause of cancer death in the United States. Standard tests such as prostate-specific antigen (PSA) measurement have poor specificity (33%) resulting in a high number of false positive reports. Consequently there is a need for new biomarkers to address this problem. The MIL-38 antibody was first described nearly thirty years ago, however, until now, the identification of the target antigen remained elusive. By a series of molecular techniques and mass spectrometry, the MIL-38 antigen was identified to be the highly glycosylated proteoglycan Glypican-1 (GPC-1). This protein is present in two forms; a membrane bound core protein of 55-60 kDa and secreted soluble forms of 40 kDa and 52 kDa. GPC-1 identification was confirmed by immuno-precipitation, western blots and ELISA. An ELISA platform is currently being developed to assess the levels of GPC-1 in normal, benign prostatic hyperplasia (BPH) and prostate cancer patients to determine whether secreted GPC-1 may represent a clinically relevant biomarker for prostate cancer diagnosis.
AbstractList Prostate cancer is the most frequently diagnosed male visceral cancer and the second leading cause of cancer death in the United States. Standard tests such as prostate-specific antigen (PSA) measurement have poor specificity (33%) resulting in a high number of false positive reports. Consequently there is a need for new biomarkers to address this problem. The MIL-38 antibody was first described nearly thirty years ago, however, until now, the identification of the target antigen remained elusive. By a series of molecular techniques and mass spectrometry, the MIL-38 antigen was identified to be the highly glycosylated proteoglycan Glypican-1 (GPC-1). This protein is present in two forms; a membrane bound core protein of 55-60 kDa and secreted soluble forms of 40 kDa and 52 kDa. GPC-1 identification was confirmed by immuno-precipitation, western blots and ELISA. An ELISA platform is currently being developed to assess the levels of GPC-1 in normal, benign prostatic hyperplasia (BPH) and prostate cancer patients to determine whether secreted GPC-1 may represent a clinically relevant biomarker for prostate cancer diagnosis.
Author Justiniano, Irene O
Campbell, Douglas H
Wissmueller, Sandra
Soon, Julie T
Walsh, Bradley J
Truong, Quach
Nocon, Aline L
AuthorAffiliation Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
AuthorAffiliation_xml – name: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
Author_xml – sequence: 1
  givenname: Quach
  surname: Truong
  fullname: Truong, Quach
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
– sequence: 2
  givenname: Irene O
  surname: Justiniano
  fullname: Justiniano, Irene O
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
– sequence: 3
  givenname: Aline L
  surname: Nocon
  fullname: Nocon, Aline L
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
– sequence: 4
  givenname: Julie T
  surname: Soon
  fullname: Soon, Julie T
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
– sequence: 5
  givenname: Sandra
  surname: Wissmueller
  fullname: Wissmueller, Sandra
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
– sequence: 6
  givenname: Douglas H
  surname: Campbell
  fullname: Campbell, Douglas H
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
– sequence: 7
  givenname: Bradley J
  surname: Walsh
  fullname: Walsh, Bradley J
  organization: Minomic International Ltd, Suite 2, Ground Floor, 75 Talavera Rd, Macquarie Park, NSW 2113, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27313791$$D View this record in MEDLINE/PubMed
BookMark eNpVUctOwzAQtFARLaUHfgD5CIeUOHbimAMSRFAqFcEBztbGcWhKahc7RSpfT_qgKnvZ1e5odjRzijrGGo3QOQmHnMTh9UzBkLCExUeoR1LKA5EkrHMwd9HA-1nYFhURZ_QEdSNOCeWC9NDzqF4tKgUmIBg8Bnxf2Tm4T-1waR1-ddY30GicgVHa3eCxtzU0lTUYTIGzKThQjXbVz2Z5ho5LqL0e7HofvT8-vGVPweRlNM7uJoGiPG6CPOWRAsaTnAumWqGpKkkkhChYHglSahYxweM0L0TKY1HEKi5AK5owCqJQlPbR7ZZ3scznulDaNA5quXBVq30lLVTy_8VUU_lhvyUTJIzFmuByR-Ds11L7Rs4rr3Rdg9F26SXhgqc8pCxtoVdbqGq98E6X-zcklOsEZJuA3CTQYi8Ode2Rf37TX-sIgxA
CitedBy_id crossref_primary_10_1002_med_21455
crossref_primary_10_1038_s41391_021_00480_8
crossref_primary_10_1021_acs_molpharmaceut_2c00760
crossref_primary_10_1038_s41598_019_47874_2
crossref_primary_10_1186_s12860_021_00361_x
crossref_primary_10_3390_biom9120820
crossref_primary_10_1016_j_drudis_2023_103660
crossref_primary_10_1038_s41419_021_03547_5
crossref_primary_10_1369_0022155420933709
crossref_primary_10_1152_ajpcell_00290_2021
crossref_primary_10_1093_labmed_lmae013
crossref_primary_10_1016_j_bj_2019_05_004
crossref_primary_10_1016_j_urolonc_2020_03_010
crossref_primary_10_1371_journal_pone_0196017
crossref_primary_10_3389_fcell_2021_781172
crossref_primary_10_1021_acs_analchem_6b02191
crossref_primary_10_1038_s41598_024_66838_9
crossref_primary_10_1080_14712598_2022_2033204
crossref_primary_10_3389_fonc_2019_00614
crossref_primary_10_1021_acssensors_9b02377
crossref_primary_10_1016_j_aca_2022_339863
crossref_primary_10_1186_s13550_020_00637_x
crossref_primary_10_1111_iju_14683
crossref_primary_10_1038_s41598_022_21656_9
crossref_primary_10_1002_cam4_1064
crossref_primary_10_2147_OTT_S315200
crossref_primary_10_3390_cancers12040984
crossref_primary_10_3390_cancers14143364
crossref_primary_10_1111_febs_15776
crossref_primary_10_3390_ijms231810279
crossref_primary_10_1021_acsnano_7b08199
crossref_primary_10_1159_000502753
crossref_primary_10_1177_17588359211022918
crossref_primary_10_1155_2022_8209700
crossref_primary_10_1016_j_pdpdt_2020_102064
crossref_primary_10_1002_advs_202402509
ContentType Journal Article
Copyright Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. 2016
Copyright_xml – notice: Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. 2016
DBID NPM
AAYXX
CITATION
7X8
5PM
DOI 10.7150/jca.14645
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1837-9664
EndPage 1009
ExternalDocumentID 10_7150_jca_14645
27313791
Genre Journal Article
GroupedDBID ---
53G
5VS
7X7
8FI
8FJ
ABDBF
ABUWG
ADBBV
ADRAZ
AENEX
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
DIK
E3Z
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IPNFZ
KQ8
M48
M~E
NPM
O5R
O5S
OK1
PGMZT
PIMPY
RIG
RPM
UKHRP
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c375t-b872ca476b794c1838cf12999d4b291fe4249758bd98759d5c5daec3643a9dc33
IEDL.DBID RPM
ISSN 1837-9664
IngestDate Tue Sep 17 20:32:09 EDT 2024
Fri Aug 16 06:18:02 EDT 2024
Fri Aug 23 01:26:14 EDT 2024
Sat Sep 28 08:20:03 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Proteoglycan
Prostate Cancer
Glypican 1
Theranostic
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-b872ca476b794c1838cf12999d4b291fe4249758bd98759d5c5daec3643a9dc33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conflict of Interest: The authors declare no conflicts of interest. The authors are employed by and are shareholders in Minomic International Ltd.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910593/
PMID 27313791
PQID 1797870348
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4910593
proquest_miscellaneous_1797870348
crossref_primary_10_7150_jca_14645
pubmed_primary_27313791
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Australia
PublicationPlace_xml – name: Australia
– name: Sydney
PublicationTitle Journal of Cancer
PublicationTitleAlternate J Cancer
PublicationYear 2016
Publisher Ivyspring International Publisher
Publisher_xml – name: Ivyspring International Publisher
References 15059894 - Cancer Res. 2004 Apr 1;64(7):2418-23
26106858 - Nature. 2015 Jul 9;523(7559):177-82
25393274 - Curr Opin Urol. 2015 Jan;25(1):59-64
19414278 - Curr Opin Chem Biol. 2009 Jun;13(3):235-44
2148568 - J Cell Biol. 1990 Dec;111(6 Pt 2):3165-76
18064304 - J Clin Invest. 2008 Jan;118(1):89-99
11454708 - Cancer Res. 2001 Jul 15;61(14):5562-9
24705158 - Genes (Basel). 2013 Mar 28;4(2):152-70
21688197 - Semin Immunopathol. 2011 Sep;33(5):441-54
9802880 - J Clin Invest. 1998 Nov 1;102(9):1662-73
2685375 - J Urol. 1989 Dec;142(6):1578-83
18309083 - Science. 2008 Feb 29;319(5867):1244-7
10783877 - Nature. 2000 Apr 13;404(6779):725-8
19011622 - Nat Cell Biol. 2008 Dec;10(12):1470-6
15499615 - Int J Cancer. 2005 Feb 20;113(5):752-60
23861782 - PLoS One. 2013 Jul 04;8(7):e67687
20643572 - Curr Opin Chem Biol. 2010 Aug;14(4):529-37
11518720 - J Clin Invest. 2001 Aug;108(4):497-501
23708103 - Int J Mol Sci. 2013 May 24;14(6):11034-60
15449043 - Cancer Immunol Immunother. 2004 Nov;53(11):995-1004
24177197 - Clin Biochem. 2014 Jul;47(10-11):889-96
25863334 - J Natl Cancer Inst. 2015 Apr 11;107(7):null
22351761 - J Biol Chem. 2012 Apr 20;287(17):14040-51
10505759 - Pancreas. 1999 Oct;19(3):281-8
22029758 - N Engl J Med. 2011 Nov 24;365(21):1951-3
3335421 - Int J Cancer. 1988 Jan 15;41(1):74-82
26139298 - Int J Cancer. 2015 Dec 15;137(12):2869-78
21155971 - J Cell Mol Med. 2011 May;15(5):1013-31
25446899 - Cancer Cell. 2014 Nov 10;26(5):707-21
21645191 - Traffic. 2011 Dec;12(12):1659-68
23161513 - Mol Cell Proteomics. 2013 Feb;12 (2):343-55
19188157 - Clin Cancer Res. 2009 Feb 1;15(3):865-75
11106655 - J Biol Chem. 2001 Mar 9;276(10):7507-17
19297564 - N Engl J Med. 2009 Mar 26;360(13):1351-4
19498381 - Nat Rev Immunol. 2009 Aug;9(8):581-93
References_xml
SSID ssj0000392743
Score 2.2757905
Snippet Prostate cancer is the most frequently diagnosed male visceral cancer and the second leading cause of cancer death in the United States. Standard tests such as...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 1002
SubjectTerms Research Paper
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3bS8MwFMYPc4L4It6tN6L42rm2adP4IjqcU6j44GBvJU0ynMxudhu4_96TthtWffC5N_olzfl9zckJwEWTai1CpW3tc2FTTgNbuJLbQcJEgLyLMcasHY6egk6XPvb8Xg0We2yWAk7-tHZmP6luNmx8fsyv8YNHfm0w5JnLN_T-jpmhW4FVFwOiyeyKSsrPB2RkgDLVHu2YqUdJixpD1aurkekXbv7MmvwWhtqbsFHyI7kpGnwLajrdhrWonCHfgeh-OB-boc12iJgQQW4Ho3eTgpMRxFPybBZ5IF6Slmnt7Io8YN_LG4eIVJHWsnxzsTpzF7rtu5dWxy63TLClx_ypnYTMlYIylJpTia8byj5GdM4VTVzu9DVFu4UWIVEcjQpXvvSV0NJDLhFcSc_bg3o6SvUBELRCfqiUh43Wp8oJuUAvmSBfMV_ypmYWnC_kisdFZYwYHYXRNEZN41xTC84WQsbYb81khEj1aDaJcSAwY4VHQwv2C2GXt0GkcjzGHQtYRfLlCaYmdvVIOnjNa2NTboDRO_zHc49gHemn_J9yDPVpNtMnSBjT5DTvP19lyc--
  priority: 102
  providerName: Scholars Portal
Title Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization
URI https://www.ncbi.nlm.nih.gov/pubmed/27313791
https://search.proquest.com/docview/1797870348
https://pubmed.ncbi.nlm.nih.gov/PMC4910593
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8JAEJ4AB-PF-LY-yGq8llK6faw3bUQ0qeEgCbdmu7tEDBTC4-C_d3bbEtCbl176SPPN7Mz3dWemAPdtqhSPpLKVz7hNGQ1s3hHMDrKQB8h3Mcfo3uHkPegN6NvQH9bAr3phTNG-yMatfDJt5eNPU1s5nwqnqhNz-klMmWYFnlOHOqbfLYluwi9mfEyLxRShEPmO8yW4DghU_6UGs7XrmYmc22noD7f8XSK5lXO6h3BQkkXyWLzUEdRUfgx7SbkdfgLJy-R7ruOY7RK-JJw8jWdTXW-zIMhFSV93dCCXJLE27eKBvKKjGUsQnksSb2Y1F62YpzDoPn_EPbv8P4ItvNBf2VkUdgSnIeLKqMC1GYkRpm_GJM06zB0pitoK9UAmGaoSJn3hS66EhySEMyk87wwa-SxXF0BQ9_iRlB5aaESlGzGOwjFDMhX6grVVaMFdBVc6L8ZgpCgfNLwpwpsaeC24rYBM0Un1zgPP1Wy9THHV68Dg0ciC8wLYzWMqi1gQ7kC-uUAPwN49g35hBmGXfnD57zuvYB8JUPlJ5Roaq8Va3SDJWGVNI87xmNCoaRzsBzi41Mo
link.rule.ids 230,314,727,780,784,864,885,2221,24318,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LTwIxEJ4gJurF-Baf1XhdYWlLt96UiKCs8YCJt023LREjC0E4-O-d7oOA3jzvI5tvpjPft52ZAlzVmLUqMNazXCqPSdbwVF1LrxEL1UC-iznG9Q6Hz432K3t8428l4EUvTFq0r-PBdfI5vE4G72lt5Xioq0WdWPUlbDLpWAGtrsAqp0L6CyI9DcCY8zExZnOEBDKe6odWLiQwd04N5mufpjM5FxPRH3b5u0hyIeu0tmAzp4vkNvusbSjZZAfWwnxDfBfCh8_vsYtknk_UF1HkbjAauoqbCUE2Sl5cTweySdJ0xp3ckA66WmoLohJDmvNpzVkz5h68tu57zbaXn5DgaSr41IsDUdeKCURWMo2rM9B9TOBSGhbXpd-3DNUVKoLYSNQl0nDNjbKaIg1R0mhK96GcjBJ7CASVDw-MoWijPjN-IBVKxxjplOBa1qyowGUBVzTOBmFEKCAcvBHCG6XwVuCiADJCN3V7Dyqxo9lXhOvehQbKggocZMDOX1NYpAJiCfL5DW4E9vIV9Ix0FHbuCUf_fvIc1tu9sBt1O89Px7CBdCj_wXIC5elkZk-Rckzjs9TBfgCQu9ZQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8JAEJ4oJsSL8W19rsZrqWW3tOtNqwhqCQdJuDXb3SVioBAeB_-9s20hoDfPfaT5Zna-b7ozswC3d0xrEShta48Lm3FWs0VVcruW-KKGehc5xvQOR61ao8Neu1535aivrGhfJv1KOhhW0v5nVls5HkpnUSfmtKOQcaMKqDNWPWcTtjyKTraSqGdBGHkfyTGfJeSj6nG-pDBhgZmzapCzXZrN5Vwloz8K83eh5Arz1Hdhp5CM5CH_tD3Y0Ok-lKNiU_wAopfB99hEM9slYkoEeeyPhqbqZkJQkZK26etARUlCY-DJPWmiu2X2ICJVJFxObM4bMg-hU3_-CBt2cUqCLanvzewk8KtSMB_R5UziCg1kD0mcc8WSKnd7mmGGhVlBojjmJlx50lNCS4pSRHAlKT2CUjpK9QkQzH68QCmKduox5QZcYPqYoKTyPcnvtG_BzQKueJwPw4gxiTDwxghvnMFrwfUCyBhd1ew_iFSP5tMY174JD5QFFhznwC5fs7CIBf4a5MsbzBjs9SvoHdk47MIbTv_95BWU20_1-L3ZejuDbVRExT-WcyjNJnN9gapjllxm_vUDsELXYw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glypican-1+as+a+Biomarker+for+Prostate+Cancer%3A+Isolation+and+Characterization&rft.jtitle=Journal+of+Cancer&rft.au=Truong%2C+Quach&rft.au=Justiniano%2C+Irene+O&rft.au=Nocon%2C+Aline+L&rft.au=Soon%2C+Julie+T&rft.date=2016-01-01&rft.issn=1837-9664&rft.eissn=1837-9664&rft.volume=7&rft.issue=8&rft.spage=1002&rft.epage=1009&rft_id=info:doi/10.7150%2Fjca.14645&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1837-9664&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1837-9664&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1837-9664&client=summon